DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Diurnal Variation of Exogenous Peptides (GH Puls/Jurgita I)

Information source: Aarhus University Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Growth Hormone Deficiency

Intervention: Norditropin SimpleXx (growth hormone) (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: Aarhus University Hospital

Official(s) and/or principal investigator(s):
Torben Laursen, professor, Principal Investigator, Affiliation: Institute of Pharmacology, Aarhus University


This is an exploratory trial with four cross-over arms measuring the pharmacokinetic and pharmacodynamic profiles of growth hormone using two different modes of growth hormone administration (subcutaneous infusion into the abdomen or subcutaneous bolus injection in the thigh) in 8 adult male or female patients with growth hormone deficiency during interval exercise or in supine rest. The order of dosing regimen within the groups and between the groups will be randomised. All patients will go through four different treatment sessions: A/B Single subcutaneous bolus injection, supine rest without/with interval exercise, sessions C/D: Continuous subcutaneous infusion, supine rest without/with interval exercise. Hypotheses: 1) There is day-to-day variation of exogenous growth hormone, 2)Concentration of growth hormone decreases due to exercise compared to supine rest, 3)There is a circadian variation in pharmacokinetics of exogenous growth hormone infused subcutaneously

Clinical Details

Official title: Pharmacokinetic Profiles of GH Using Two Different Administration Regimes; a Bolus and an Infusion Both With and Without Exercise, in Adults With Growth Hormone Deficiency

Study design: Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Pharmacokinetic profiles of growth hormone

Secondary outcome: Pharmacokinetic profiles of growth hormone

Detailed description: The subjects will attend a screening visit and four treatment sessions. The dosing visits will comprise either 2-day hospital stay for the bolus injection group or 3 day hospital stay for the infusion group.


Minimum age: 18 Years. Maximum age: 75 Years. Gender(s): Both.


Inclusion Criteria:

- AGHD male or female subjects

- Stable GH replacement therapy for at least 3 months

- Body Mass Index 18,5 to 35. 0 kg/m2

- Achieved final height

- Age ≥ 18 years

Exclusion Criteria:

- Known or suspected allergy to trial product or components of the trial product

- Subjects with active malignancy

- Severe cardiac insufficiency classified according to NYHA III-IV

- Unstable angina pectoris, acute myocardial infarction within the last 12 months

- Severe, uncontrolled hypertension: sitting blood pressure > 180/110 mmHg

- HbA1C > 7,5 %

- Impaired kidney function: plasma creatinine ≥ 150 umol/l according to the hospital


- Impaired liver function: liver parameters exceed 2 times or more the upper normal

limit, according to the hospital lab.

- Patients on insulin treatment

- Stable pituitary replacement therapy for less than 3 months

- Participation in any other clinical trial involving any investigational products

within the last three months prior to this trial

- Any diseases judged by the investigator that could affect the trial

- Women of fertile age, who are pregnant, planning to become pregnant or

breast-feeding. Women of fertile age, who are not currently using adequate contraception methods such as: contraceptive pills, IUD or who had not undergone hysterectomy or sterilization

Locations and Contacts

Aarhus University Hospital, Aarhus C 8000, Denmark

Medical Department M, Aarhus University Hospital, Aarhus C, Central Denmark Region 8000, Denmark

Additional Information

Starting date: October 2010
Last updated: January 8, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017